Abstract: Disclosed herein is a method for producing an elongated (rolled) carbonaceous film by polymer pyrolysis while suppressing the fusion bonding and the rippling of the carbonaceous film. The method for producing a carbonaceous film includes the step of heat-treating a polymer film wound into a roll, wherein the heat treatment is performed after the polymer film is wound into a roll at a temperature lower than a pyrolysis onset temperature of the polymer film so that the roll of polymer film has a center and has a space inside its cross-sectional circle (50% cross-sectional circle) (space within 50% cross-sectional circle) whose center is at the center and whose circumference passes through a point at which a length of the polymer film from an inner end thereof is 50% of a total length of the polymer film and that an area of the space within 50% cross-sectional circle is 25% or more of an area of the 50% cross-sectional circle.

Abstract: A method of forming mono-crystalline diamond by chemical vapor deposition, the method comprising the steps of: (a) providing at least one diamond seed; (b) exposing the seed to conditions for growing diamond by chemical vapor deposition, including supplying reaction gases that include a carbon-containing gas and hydrogen for growing diamond and include a nitrogen-containing gas; and (c) controlling the quantity of nitrogen-containing gas relative to other gases in the reaction gases such that diamond is caused to grow by step-growth with defect free steps without inclusions. The nitrogen is present in the range of 0.0001 to 0.02 vol %. Diborane can also be present in a range of from 0.00002 to 0.002 vol %. The carbon-containing gas can be methane.

Abstract: Disclosed is a composition containing carbon nanotubes which meets all of the following conditions (1) to (4). (1) When observed via transmission electron microscopy, at least 50 out of every 100 carbon nanotubes are double-walled carbon nanotubes. (2) The carbon nanotubes have an average outer diameter in the range of 1.0 to 3.0 nm. (3) During thermogravimetric analysis under atmosphere at a temperature increase rate of 10° C./minute, a high temperature combustion peak is at 700 to 850° C., and the relationship between low temperature weight loss (TG(L)) and high temperature weight loss (TG(H)) is TG(H)/(TG(L)+TG(H))?0.75. (4) The composition containing carbon nanotubes has a volume resistance value between 1.0×10?2 ?·cm and 1.0×10?4 ?·cm, inclusive. The disclosed composition containing carbon nanotubes primarily has double-walled carbon nanotubes with high electrical conductivity and high heat resistance.

Abstract: A method of producing carbon fibers, in which the producing method comprises allowing a supported type catalyst and a carbon atom-containing compound to come in contact with each other in a heating zone, wherein the supported type catalyst is prepared by a method comprising impregnation of a powdery carrier with colloid containing catalyst to support particles of the catalyst on the powdery carrier having a specifically developed crystal plane such as a powdery carrier being 4 or more in the ratio (I1/I2) of the intensity I1 of the strongest peak to the intensity I2 of the second strongest peak observed in X-ray diffraction, or a powdery carrier having the ratio (I1/I2) of the intensity I1 of the strongest peak to the intensity I2 of the second strongest peak observed in X-ray diffraction of 1.5 times or more the ratio (I1s/I2s) of the intensity I1s of the strongest peak to the intensity I2s of the second strongest peak described in JCPDS.

Abstract: [Subject] Manufacturing onion-like carbon at a low cost. [Means for Realizing Subject] According to the invention, DLC powder, which is hard carbon powder, is produced by plasma CVD using a hydrocarbon gas as a material gas, in a first step, i.e. a DLC powder producing processing step. Then, in a second step, i.e. a DLC-to-OLC converting processing step, the DLC powder is heated in a vacuum or in an inert gas atmosphere to thereby convert the DLC powder into OLC. Like this, according to the invention, since a hydrocarbon gas can be used as a starting material to manufacture OLC, OLC can be manufactured at a significantly low cost.

Abstract: In various embodiments, the present disclosure describes processes for preparing functionalized graphene nanoribbons from carbon nanotubes. In general, the processes include exposing a plurality of carbon nanotubes to an alkali metal source in the absence of a solvent and thereafter adding an electrophile to form functionalized graphene nanoribbons. Exposing the carbon nanotubes to an alkali metal source in the absence of a solvent, generally while being heated, results in opening of the carbon nanotubes substantially parallel to their longitudinal axis, which may occur in a spiralwise manner in an embodiment. The graphene nanoribbons of the present disclosure are functionalized on at least their edges and are substantially defect free. As a result, the functionalized graphene nanoribbons described herein display a very high electrical conductivity that is comparable to that of mechanically exfoliated graphene.

Abstract: Ultra-high purity zinc bromide and quaternary ammonium bromides suitable for use in zinc-bromine batteries, and methods for making same, are provided.

Abstract: Disclosed are methods for producing ZnO nanostructures, the methods comprising heating an aqueous solution comprising a zinc compound, a base, and a polymer which is polyvinylpyrrolidinone or poly(ethylene glycol).

Abstract: A method is disclosed for preparing crystalline aluminosilicate X zeolite from a reaction mixture containing only sufficient water to produce X zeolite. In one embodiment, the reaction mixture is self-supporting and may be shaped if desired. In the method, the reaction mixture is heated at crystallization conditions and in the absence of an added external liquid phase, so that excess liquid need not be removed from the crystallized product prior to drying the crystals.

Abstract: A new family of coherently grown composites of TUN and IMF zeotypes have been synthesized. These zeolites are represented by the empirical formula. NanMmk+TtAl1?xExSiyOz where “n” is the mole ratio of Na to (Al+E), M represents a metal or metals from zinc, Group 1, Group 2, Group 3 and or the lanthanide series of the periodic table, “m” is the mole ratio of M to (Al+E), “k” is the average charge of the metal or metals M, T is the organic structure directing agent or agents, and E is a framework element such as gallium. These zeolites are similar to TNU-9 and IM-5 but are characterized by unique compositions and synthesis procedures and have catalytic properties for carrying out various hydrocarbon conversion processes and separation properties for carrying out various separations.

Abstract: Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide bridges, hydrocarbon bridges, and their combinations, salts and derivatives thereof wherein the cyclic analog is more stable than a non-cyclic analog when incubated in the presence of enzymes that degrade GLP-1 and have an increased serum half-live, wherein the cyclic analog comprises at least a portion of a GLP-1 peptide or at least a portion of an Exendin peptide salts, derivatives or combinations thereof.

Abstract: The present invention relates to an image enhancing composition for the enhancement of contrast in a body cavity, wherein the viscosity of the composition is between 2000 and 4000 mPa·sec. It also relates to a method for enhancing contrast of an image of a body cavity, which method involves introducing one single small aliquot of an image enhancing composition into the body cavity. In another aspect, the present invention provides a high contrast image of a body cavity obtained by the method of the invention, in particular a 3-dimensional high contrast image.

Abstract: A contrast agent for angiography is disclosed, in particular, for examining animal or human bodies or components thereof such as members or organs thereof, comprising an essentially oil-based apolar contrast component for X-ray examinations, the contrast component having a contrast component viscosity in the range of 30-100 mPas. The contrast agent is characterized in that the contrast component is present in a mixture with at least one further apolar component, the viscosity of which is less than or at most equal to the contrast component viscosity. Methods for angiography examination are also disclosed, in which such a contrast agent or also a polar contrast agent are used at least periodically and applications of such contrast agents.

Abstract: A freshening composition having a malodor control component, about 1% to about 5% of low molecular weight monohydric alcohols, and an aqueous carrier are provided. The composition is essentially free of any material that would soil or stain fabric. The composition may be delivered to fabrics and/or air. The malodor control component may include an effective amount of volatile aldehydes and/or an acid catalyst.

Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.

Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by affecting PMP22 expression in a subject.

Abstract: The invention concerns the use of a deoxy hesperetin dihydrochalcone or a salt of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of a plurality of salts of the deoxy hesperetin dihydrochalcone (I) or a mixture comprising or consisting of deoxy hesperetin dihydrochalcone (I) and a salt or a plurality of salts of the deoxy hesperetin dihydrochalcone (I), to influence the strength of taste impressions of sweet-tasting, unpleasant-, in particular bitter-, tasting or both sweet- and unpleasant-, in particular bitter-, tasting substances or mixtures of substances.

Abstract: In an embodiment, the barrier-forming composition includes a carbohydrate gum, a humectant, and an antimicrobial agent. The composition furthermore meets the following requirements: about 0.01%?C?about 0.4%; about 4.5%?H?about 65%; and 0.050%<A; or about 0%?C?about 0.4%; about 55%?H?about 65%; and 0.050%<A. C is the carbohydrate gum; H is the humectant; and A is the antimicrobial agent. All percentages are by weight of the total composition. In an embodiment the barrier-forming composition has an Rf value in water of 0 to about 0.25.

Abstract: An oral stain remover which can remove a stain or a dental plaque effectively without a need of brushing the surface of teeth with a toothbrush or the like, and an oral composition containing the stain remover. An oral stain remover contains a salt of ultraphosphoric acid, and an oral composition contains the oral stain remover.

Abstract: The instant disclosure relates to sunscreen compositions. The sunscreen compositions include (a) at least one UV filter (b) at least one booster, (c) at least one thermosensitive polymer, and (d) at least one wetting agent. Sunscreen compositions comprising components (a)-(d) exhibit a surprisingly high sun protection factor (SPF). The disclosure further relates to methods of using the sunscreen compositions for protecting keratinous substances such as skin and hair from UV radiation.

Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.

Abstract: Compositions and methods for lightening and/or depigmenting skin are provided, the compositions comprising compounds having the structure: or having the structure: as defined herein.

Abstract: Products and methods are disclosed for reducing the production of unwanted odors on the human body.

Abstract: Disclosed herein are cosmetic compositions comprising at least one film-forming polymer, at least one silicone elastomer blend, and at least one wax. Also disclosed herein are methods for making up and/or enhancing the appearance of a keratinous substrate comprising applying said composition to the keratinous substrate.

Abstract: A process for shaving that includes the steps of moisturizing the hair, using a sealing agent for sealing the moisture inside the hair keeping the moisture in the hair while smoothing the skin to be shaved applying mineral oil to the hair and skin to create a buffer for the lubricating agent that is applied next. Then, using sufficient water to form a lather. Next, the moisture from the blade after the blade is washed with water by utilizing alcohol. In the final step of the process oil is applied to the blades to prevent contact with the atmospheric moisture and thus extending its useful life.

Abstract: The invention is in the field of skin hygiene, especially hand hygiene and/or hand soap compositions. It remains to be desired to prepare skin hygiene compositions having a high anti-microbial effect, even with a low dosage of anti-microbial essential oils. It is therefore an object of the invention to provide a skin hygiene composition, having good anti-microbial properties, at low levels of essential oil. Surprisingly it has been found that composition comprising a low amount of at least two essential oils and a polymer provides improved hygiene efficacy.

Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.

Abstract: The invention relates to a cosmetic composition comprising at least one non-elastomer, filmogenic, linear, sequenced, ethylenic polymer and in a cosmetically acceptable liquid medium and a gelling agent of said organic liquid medium. The invention also relates to the combination of said sequenced polymer and a gelling agent in order to improve the texture and application of said composition on keratin fibers.

Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.

Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.

Abstract: Embodiments herein relate to compositions and methods for engraftment of and increasing survival of muscle cells in a subject in need thereof. In certain embodiments, compositions including myofibers and/or satellite stem cells may be administered to a subject. Other embodiments relate to compositions and methods for introducing one or more compounds to a subject using cell compositions disclosed herein. Still other embodiments relate to uses of these compositions in kits for portable applications and methods.

Abstract: Compositions comprising human Tr1 cells directed to a food antigen from common human diet and methods for treating an intestinal inflammatory condition.

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.

Abstract: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods to control bone loss, treat bone disease and prevent tumor growth in bones of individual.

Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.

Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.

Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.

Abstract: A water soluble globulin concentrate is described. The globulin concentrate is administered through the animals' water supply and is effective in increasing growth and weight gain in animals. The concentrate is especially effective in reducing morbidity in underweight, stressed pigs, post-weaning.

Abstract: The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and ICE. The combination of CD37 antibodies and ICE is shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.

Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.

Abstract: Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent.

Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.

Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.

Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.

Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Abstract: The present invention relates to the use of an inhibitor of tailless gene expression or tailless protein activity for the preparation of a pharmaceutical composition for treating or preventing the brain tumor in a subject. Preferably an inhibitor of tailless expression is a single or double stranded RNA. An inhibitor of tailless protein activity is preferably an antibody which specifically binds thereto. Finally, the invention includes methods for identifying anti-brain tumor drugs.

Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.

Abstract: Chimeric molecules comprising receptor activator of NF-?B ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.